RecruitingPHASE1, PHASE2NCT04521231
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Studying Acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Amgen
- Principal Investigator
- MDAmgen
- Intervention
- Blinatumomab(drug)
- Enrollment
- 281 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2021 – 2029
Study locations (30)
- University of California San Francisco Fresno at Community Cancer Institute, Clovis, California, United States
- City of Hope National Medical Center, Duarte, California, United States
- University of Illinois Chicago, Chicago, Illinois, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- C.S. Mott Children's Hospital - University of Michigan, Ann Arbor, Michigan, United States
- Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
- New York University Grossman School of Medicine and New York University Langone Hospitals, New York, New York, United States
- Albert Einstein College of Medicine - Montefiore Medical Center, The Bronx, New York, United States
- Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- St Jude Childrens Research Hospital, Memphis, Tennessee, United States
- University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- Fred Hutchinson Cancer Center, Seattle, Washington, United States
- The Medical College of Wisconsin, Milwaukee, Wisconsin, United States
- Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
- Sanatorio Allende, Córdoba, Córdoba Province, Argentina
- +15 more locations on ClinicalTrials.gov
Collaborators
BeOne Medicines
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04521231 on ClinicalTrials.govOther trials for Acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05621291A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...National Cancer Institute (NCI)
- RECRUITINGPHASE2NCT07328503CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06738368Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaUniversity of Washington
- ENROLLING BY INVITATIONNCT07511959Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative DentistryWroclaw Medical University
- RECRUITINGNANCT07191119Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic LeukemiaSt. Jude Children's Research Hospital
- RECRUITINGNANCT07177183Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning FailureUniversity Hospital Ostrava
- RECRUITINGPHASE2NCT07275762Y-4 to Treat the Postherpetic NeuralgiaNeurodawn Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07201974Virtual Reality for Post-Stroke Gait RehabilitationMcGill University